Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Andrew Booth is Chief Financial Officer at Abcellera Biologics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Nov 13, 2026, each linked to the official Form 4.
Chief Financial Officer
Disclosures on record
1
Companies involved
1
Nov 13, 2026Bought~$97K
DetailsOfficial recordAs of the latest filing on , Andrew Booth reported holding 491,400 shares of Abcellera Biologics (ABCL), worth about $5.65M at the last close of $11 (Nov 13, 2026). In the last 12 months, Andrew Booth bought $97K in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Abcellera Biologics ABCL | 491,400 | 491K direct | $11 | $5.65M | Nov 13, 2026 |
Is this Andrew Booth’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Nov 13, 2026, Andrew Booth reported holding 491,400 shares of Abcellera Biologics (ABCL). At the last close of $11 on Nov 13, 2026, that is about $5.65M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Andrew Booth reported 1 open-market purchase worth $97K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Andrew Booth bought shares on the open market in 2021, 2022, 2023 and 2026. Sales in 1 of the 6 years since 2021.
In SEC filings since 2021: the latest open-market purchase is from 2026; the latest open-market sale is from 2021.
Abcellera Biologics (ABCL), from 2021 to 2026: 5 purchases and 1 sale.
Andrew Booth bought shares on the open market in 2021, 2022, 2023 and 2026. Sales in 1 of the 6 years since 2021.
Andrew Booth reported 5 open-market purchases and 1 sale since 2021; purchases in 4 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $97K1×1 trade | — |
| 2023 | $99K1×1 trade | — |
| 2022 | $492K1×1 trade | — |
| 2021 | $993K2×2 trades | $30.6M1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Andrew Booth reported 5 open-market purchases and 1 sale here, 2021 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
